AI drug discovery

AITRICS VItal Care software
By  Adam Ang 02:53 am November 4, 2022
South Korea clears AITRICS' AI software for predicting patient deterioration AI startup AITRICS has obtained clearance from South Korea's Ministry of Food and Drug Safety for its AI monitoring solution. The South Korean startup has developed VitalCare, an AI software for predicting a patient's risk of cardiac arrest, sepsis and death within 4-6 hours in the ICU. It tracks six vital parameters, 11...
Screenshot of the Fred Marketplace online portal
By  Adam Ang 01:14 am August 19, 2022
Fred launches third-party apps marketplace for pharmacies Australian pharmacy IT solutions provider Fred IT Group has launched an online marketplace of third-party applications for pharmacies. Called Fred Marketplace, the web-based hub has solutions that have been approved and tested for use with Fred's software, including apps and integrations for robots, eCommerce, business intelligence,...
Anura mobile app by NuraLogix
By  Adam Ang 10:50 pm June 2, 2022
NuraLogix introduces health measurement app in Singapore Canadian health AI company NuraLogix has introduced its mobile health measurement app in Singapore. Anura uses proprietary transdermal optical imaging technology, which captures blood information from a person's face through a video camera. It can measure various vital parameters, including blood pressure, heart rate, stress level, cardiac...
A researcher holding an injection and a vial of drug
By  Adam Ang 05:19 am May 19, 2022
ICT provider Fujitsu has partnered with research institute Riken in Japan to jointly work on new-generation IT drug discovery technology to accelerate digital transformation in drug discovery. According to a press statement, the organisations will utilise the supercomputer Fugaku, which they have developed together in the past decade, along with simulation AI technologies. Through these...
A researcher in a lab looking at a tablet
By  Emily Olsen 01:04 pm April 5, 2022
AI-enabled pathology company PathAI has entered into a multiyear drug discovery partnership with pharma giant GlaxoSmithKline. The agreement will focus on advancing clinical trials and drug development in oncology and for nonalcoholic steatohepatitis (NASH), an aggressive type of fatty liver disease that can lead to serious scarring and liver failure.  "Our partnership will combine GSK and PathAI...
Holmusk's digital real-world evidence platform NeuroBlu
By  Adam Ang 09:18 pm February 10, 2022
Holmusk signs tech use with US-based mental healthcare provider  US-based Metrocare Services has signed an agreement with Holmusk, a behavioural health tech provider from Singapore, to use its real-world data platform in enhancing mental health care. Metrocare is a leading provider of mental health and developmental disability services in Texas.  The deal is for the use of NeuroBlu, a data...
Researcher
By  Laura Lovett 03:17 pm January 10, 2022
Biopharma giant Sanofi is setting its sights on AI for drug discovery, inking a deal worth more than $100 million with tech company Exscientia.  As part of the deal, Exscientia is eligible for as much as $5.2 billion in payments for clinical development, regulatory and commercial milestones.  The deal will revolve around the development of up to 15 novel small molecule candidates in oncology and...
Photo of different coloured drugs
By  Adam Ang 03:25 am December 1, 2021
South Korean AI drug discovery firm Standigm has signed a memorandum of understanding with non-profit research institute Institut Pasteur Korea to collaborate in discovering new anti-tubercular drug candidates. WHAT IT'S ABOUT This latest partnership is building on the companies' previous research collaboration where they were able to identify "effective" hit compounds with several key scaffolds...
Two scientists in a lab looking at a tablet
By  Emily Olsen 01:22 pm November 9, 2021
DeepCure, developer of small molecule therapeutics using an AI-enabled drug discovery platform, raised $40 million in Series A funding. The round was led by Morningside Ventures with participation from existing investors TLV Partners, Sapir Venture Partners and Benon Group Ltd. DeepCure said the Series A brings its total raise to $47 million. WHAT IT DOES The company uses its AI engine to develop...
A mix of drugs
By  Adam Ang 04:03 am September 30, 2021
Israeli startup CytoReason has made its entry into Japan – the world's third-largest pharmaceutical market, upon signing a collaboration with Summit Pharmaceuticals International, the drug research and development arm of Sumitomo Corporation, one of the world's biggest general trading firms. WHAT THEY DO CytoReason develops computational disease models for drug discovery and development using...